Should I Take My Blood Thinner If I Hit My Head?

Do not skip or take your blood thinner based on a guess after hitting your head. Call your prescriber or go to an emergency department first. The reason this question matters so much is that blood thinners increase the risk of bleeding inside the skull after even a minor bump, and that bleeding can develop hours or days later with no obvious symptoms at first. Around 5 to 9 percent of people on common blood thinners who experience minor head trauma develop intracranial hemorrhage, depending on the drug and the study, which is roughly double the rate seen in people not on these medications. The right move after a head hit is to get medical guidance quickly, because the decision to hold or continue your medication depends on the severity of the injury, the type of blood thinner you take, and your personal clotting risk.

Why Blood Thinners Make Head Injuries More Dangerous

When you hit your head, small blood vessels inside the skull can tear. In most people, the body’s clotting system seals those tears before they become a problem. Blood thinners work by interfering with that clotting system, which is exactly why they protect you from strokes and blood clots but also why even a low-energy bump can turn into a serious bleed. A systematic review and meta-analysis of prospective studies found that roughly 9 percent of patients on vitamin K antagonists like warfarin who sustained a minor head injury developed intracranial hemorrhage.¹ A separate emergency department study found the bleeding risk in anticoagulated patients was about twice that of patients not on any blood-thinning therapy.²

The concern isn’t limited to dramatic injuries. Elderly patients on anticoagulants are more likely to develop serious bleeding from low-energy events like falling from a standing position.³ A stumble in the bathroom or bumping your head on a cabinet door might seem trivial, but on blood thinners the consequences can be outsized compared to the force of the impact.

What You Should Actually Do Right After a Head Hit

If you are on any blood thinner and you hit your head hard enough to notice it, the safest course is to seek medical evaluation promptly. This does not necessarily mean a full-blown emergency for every light tap, but the threshold for getting checked should be much lower than it would be for someone not on these medications. In practical terms, that means calling your doctor’s office or going to an emergency department, even if you feel fine. Many hospitals now use rapid-assessment protocols for anticoagulated patients with head trauma, which have been shown to cut the time from arrival to CT scan nearly in half and shorten hospital stays significantly.⁴

Do not independently stop taking your blood thinner without medical advice. The instinct to skip a dose “just in case” is understandable, but stopping abruptly carries its own danger. If you are on a blood thinner for atrial fibrillation, a mechanical heart valve, or a recent blood clot, even a brief gap in therapy can expose you to a stroke or pulmonary embolism. The decision to hold a dose or continue must weigh both sides of the equation, and your doctor is the person who can make that call based on your specific situation.

Symptoms worth heading to the ER immediately for include any loss of consciousness (even briefly), confusion, persistent or worsening headache, vomiting, slurred speech, weakness on one side, or a seizure. But keep in mind that intracranial bleeding in anticoagulated patients can start without obvious neurological symptoms at first, which is part of what makes these injuries tricky.

The Problem of Delayed Bleeding

One of the most unsettling aspects of head injuries on blood thinners is that an initial brain scan can come back clean, only for bleeding to show up hours or days later. Up to about 6 percent of anticoagulated patients who sustain a head injury develop what is called a delayed intracranial hemorrhage, often within the first 24 hours, even when early imaging looks normal.⁵ One case report describes a 66-year-old man on anticoagulants who developed a subdural hematoma 48 hours after a mild head injury, despite a completely normal initial CT scan.⁶

How common is this delayed bleeding in practice? The numbers vary depending on the drug and how studies define “delayed.” One meta-analysis looking at patients who had a normal first CT scan found that about 0.6 percent went on to develop bleeding on a repeat scan 24 hours later, and the resulting risk of needing surgery or dying was about 0.13 percent.⁷ A separate meta-analysis focusing on patients specifically taking newer oral anticoagulants found delayed bleeding rates around 2.4 percent for those drugs, which was comparable to the rate seen with warfarin at about 2.3 percent.⁸ Another systematic review pooling 15 studies and over 1,300 patients on newer anticoagulants found 20 cases of delayed bleeding; most were managed without surgery, though one patient on apixaban died.⁹

This is why many emergency departments observe anticoagulated head-trauma patients for an extended period, sometimes repeating the CT scan after 24 hours. One prospective observation protocol found that 6 percent of patients with an initially normal scan developed a new hemorrhage on the repeat scan, and that having a very elevated INR (a measure of how “thin” the blood is with warfarin, above 3.0) increased the risk of delayed bleeding dramatically, with a relative risk of 14.¹⁰ Two patients in that study were discharged after two clean scans and still came back days later with symptomatic subdural hematomas. Both had initial INR values above 3.0.

Not All Blood Thinners Carry the Same Risk

The type of medication you take matters. The older drug warfarin has consistently been linked to higher rates of intracranial bleeding and worse outcomes after head trauma compared to the newer class of drugs known as direct oral anticoagulants, or DOACs (these include apixaban, rivarbacan, edoxaban, and dabigatran). In one large trauma registry study, warfarin was associated with a mortality rate of about 21 percent after traumatic intracranial bleeding compared with roughly 5 percent for DOAC users, along with a much higher rate of surgical intervention.¹¹ A study of elderly patients found similar trends: warfarin users developed intracranial hemorrhage at a rate of 57 percent versus 42 percent in DOAC users after traumatic brain injury, and DOAC patients had better functional outcomes at discharge.¹²

An updated meta-analysis found that the overall risk of a bad outcome (intracranial hemorrhage, need for surgery, or death) was about 3.2 percent for patients on DOACs who had minor head injuries, lower than the roughly 9 percent figure seen with warfarin in earlier analyses.¹³ The clinical takeaway is that while DOACs appear safer in this scenario, they are not risk-free. The same careful evaluation after a head hit applies regardless of which anticoagulant you are prescribed.

Antiplatelet Drugs Like Aspirin Are Not Harmless Either

People sometimes think “I’m only on a baby aspirin, so I’m fine.” That is not entirely true. Antiplatelet drugs work differently from anticoagulants, but they still impair the body’s ability to stop bleeding. A large study of blunt head trauma patients found that aspirin alone carried a modestly increased risk of intracranial injury compared to people on no blood-thinning drugs, and that patients on dual antiplatelet therapy (aspirin combined with another antiplatelet drug like clopidogrel) had nearly triple the risk of significant intracranial injury.¹⁴

A recent study of geriatric emergency department patients who fell confirmed this pattern: aspirin users and those on dual antiplatelet therapy had increased adjusted odds of intracranial hemorrhage compared to patients not on antiplatelet therapy, while a P2Y12 inhibitor alone (drugs like clopidogrel taken without aspirin) did not show the same elevation in risk.¹⁵ Another single-center retrospective study found that dual antiplatelet therapy was actually associated with a higher risk of traumatic intracranial hemorrhage than anticoagulation therapy alone after ground-level falls.¹⁶

The point is not to scare people off aspirin, which provides important protection for many cardiac patients. Rather, if you are taking any kind of blood thinner, including over-the-counter aspirin, the same “get checked after a head hit” advice applies.

Reversal Agents and What Hospitals Can Do

If you arrive at an emergency department with a head injury and evidence of bleeding on a CT scan, the medical team has tools to counteract your blood thinner quickly. For warfarin, reversal typically involves vitamin K and a concentrated clotting factor product called prothrombin complex concentrate that can restore clotting within minutes. For the newer DOACs, specific reversal agents have been developed: idarucizumab reverses dabigatran, and andexanet alfa targets the factor Xa inhibitors like apixaban and rivaroxaban. Strategies for reversing these drugs are constantly evolving as newer agents become available.¹⁷

This is one area where DOACs have a practical advantage. Their effects wear off faster than warfarin’s even without a reversal agent, typically within 12 to 24 hours, which partly explains the lower mortality rates seen in DOAC users after traumatic brain bleeding. If you are on warfarin and your INR runs high (above 3.0), the bleeding risk after head trauma climbs steeply, as noted earlier. Keeping your INR in the therapeutic range through regular monitoring reduces this danger.

When Anticoagulation Gets Restarted After a Head Bleed

If a head injury does lead to intracranial bleeding and your anticoagulant is stopped, the next question becomes when to restart it. This is one of the hardest judgment calls in medicine, because restarting too early risks making the brain bleed worse while waiting too long risks the stroke or clot the drug was preventing in the first place. Almost all experts agree that restarting is eventually the right move. A global survey of neurologists, neurosurgeons, and thrombosis specialists found 98 percent believed anticoagulation should be resumed after traumatic intracranial hemorrhage, though there was wide disagreement about timing.¹⁸

The limited evidence available suggests a window of roughly 7 to 14 days after the bleed may be the safest time to resume. One study found that patients who restarted anticoagulation in that range, particularly around day 10, had the fewest adverse events at six months and the lowest mortality.¹⁹ A study of patients with mechanical heart valves, who are at very high clotting risk, found no increased hazard of bad outcomes when anticoagulation was resumed within 7 days compared to 7 to 30 days after intracranial hemorrhage.²⁰ The researchers themselves have called for more randomized trials, acknowledging that the current evidence, while informative, is not definitive.

If You Fall Frequently, Should You Even Be on a Blood Thinner?

This question comes up a lot, especially among older adults and their families. The worry is intuitive: if you are prone to falling, and blood thinners make falls more dangerous, should you stop taking the medication? The answer, counterintuitively, is usually no. Large trial analyses have examined this directly. A subgroup analysis of the ENGAGE AF-TIMI 48 trial found that patients at increased risk of falling did have higher rates of major bleeding and death compared to patients who never fell, but the benefit of anticoagulation for stroke prevention still held. In fact, edoxaban showed a greater absolute reduction in intracranial hemorrhage compared to warfarin in the fall-prone group than in non-fallers.²¹ Similar subgroup analyses from the ARISTOTLE trial of apixaban reached comparable conclusions.²²

The math behind this is that you would need to fall dozens or even hundreds of times per year before the cumulative bleeding risk would outweigh the stroke-prevention benefit. For most patients, the risk of a disabling stroke without anticoagulation dwarfs the risk of a catastrophic head bleed from an occasional fall. That said, a physician reviewing a patient’s individual bleeding and stroke risk scores might sometimes decide that the balance tips the other way, particularly if someone has already had a brain bleed or has extremely frequent falls. For patients at very high bleed risk who cannot safely stay on blood thinners, procedural alternatives like left atrial appendage closure have shown similar stroke-prevention efficacy with significantly lower rates of clinically relevant bleeding compared to DOACs.²³

Blood Biomarkers May Change How Doctors Handle This

One of the frustrations with the current approach is that many patients end up sitting in an emergency department for hours or getting repeat CT scans just to rule out a bleed that never materializes. Researchers are working on blood tests that could help triage these situations faster. Two brain-injury biomarkers, called GFAP and UCH-L1, are showing promise. A prospective study of high-risk mild head injury patients found that elevated levels of these markers were strongly associated with abnormalities on CT scans, with a sensitivity of 96 percent for detecting bleeding. Among patients with negative baseline CT scans, delayed intracranial hemorrhage occurred in fewer than 1 percent, and no patient with negative biomarker results at admission developed delayed bleeding at all.²⁴

If these biomarkers prove reliable in larger validation studies, they could eventually allow emergency physicians to safely discharge low-risk anticoagulated patients much sooner after a head injury, rather than keeping everyone for observation. The specificity is still limited, meaning the tests sometimes flag people who turn out to be fine, but a negative result appears to be very reassuring. For now this remains a research tool rather than standard practice in most hospitals, but it represents a real shift in how head injuries on blood thinners could be managed in the coming years.